Pfizer Inc. (NYSE:PFE) Stock Holdings Lowered by Letko Brosseau & Associates Inc.

Letko Brosseau & Associates Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 0.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 3,847,588 shares of the biopharmaceutical company’s stock after selling 16,400 shares during the period. Pfizer accounts for 2.1% of Letko Brosseau & Associates Inc.’s portfolio, making the stock its 16th biggest holding. Letko Brosseau & Associates Inc. owned about 0.07% of Pfizer worth $97,498,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Geode Capital Management LLC grew its position in Pfizer by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company’s stock valued at $3,190,131,000 after buying an additional 2,923,537 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in Pfizer by 7.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock valued at $2,029,604,000 after buying an additional 5,350,381 shares in the last quarter. Northern Trust Corp grew its position in Pfizer by 7.7% in the 4th quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company’s stock valued at $1,548,889,000 after buying an additional 4,167,222 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Pfizer by 3.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company’s stock valued at $1,045,351,000 after buying an additional 1,333,740 shares in the last quarter. Finally, Invesco Ltd. grew its position in Pfizer by 9.6% in the 4th quarter. Invesco Ltd. now owns 29,458,139 shares of the biopharmaceutical company’s stock valued at $781,524,000 after buying an additional 2,579,455 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE PFE opened at $24.30 on Wednesday. The company has a 50 day simple moving average of $24.34 and a 200-day simple moving average of $24.63. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The firm has a market capitalization of $138.13 billion, a price-to-earnings ratio of 17.61, a price-to-earnings-growth ratio of 0.88 and a beta of 0.58. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm’s revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.82 earnings per share. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.08%. The ex-dividend date is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is 124.64%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on PFE shares. BMO Capital Markets decreased their target price on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. TD Cowen lowered their price objective on shares of Pfizer from $32.00 to $28.00 and set a “hold” rating on the stock in a research note on Tuesday, April 22nd. UBS Group lifted their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. The Goldman Sachs Group lifted their price objective on shares of Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Finally, Wolfe Research lifted their price objective on shares of Pfizer from $22.00 to $23.00 and gave the stock an “underperform” rating in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.